Scarica l'app Stockscreener
5.08
2.63%
0.13
Dopo l'orario di chiusura:
5.13
0.05
+0.98%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Champions Oncology Inc Borsa (CSBR) Ultime notizie
NMAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR - TradingView
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push - The Globe and Mail
Is Champions Oncology (NASDAQ:CSBR) In A Good Position To Invest In Growth? - Sahm
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ... By GuruFocus - Investing.com Canada
Champions Oncology Inc. (CSBR) Slides 8.75% as Selling Pressure IntensifiesVolume Spike Alerts - dars.gov.et
Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Champions Oncology Inc (CSBR) Institutional Confidence - TradingKey
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue By Investing.com - Investing.com Nigeria
Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Champions Oncology Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue - Investing.com
CSBR: Record revenue and positive Adjusted EBITDA achieved, with strong core services growth and margin gains - TradingView
CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary - TradingView
CSBR: Revenue up 4.4% to $59.4M, but net loss of $1.2M driven by higher R&D and operating costs - TradingView
Rising costs push Champions Oncology (NASDAQ: CSBR) into 2026 loss - Stock Titan
Champions Oncology, Inc. Reports Earnings Results for the Full Year Ended April 30, 2026 - marketscreener.com
Champions Oncology reports record $59.4M revenue, positive adjusted EBITDA for FY2026 - TradingView
CSBR: Record revenue and positive adjusted EBITDA achieved, driven by core research services growth - TradingView
CHAMPIONS ONCOLOGY ($CSBR) Releases Q4 2026 Earnings - Quiver Quantitative
Champions Oncology Q4 revenue rises; margin improves driven by cost discipline - TradingView
Champions Oncology Reports Record Annual Revenue of $59 Million - Eagle-Tribune
BRIEF-Champions Oncology Q4 Adjusted EPS USD 0.01 - TradingView
At fiscal year-end, Champions Oncology had $4.9M cash, no debt - Stock Titan
Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CSBR|Champions Oncology Inc|Price:6.160|Chg%:+0.030 - TradingKey
Champions Oncology, Inc. Revenue Breakdown – MUN:2I3 - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – MUN:2I3 - TradingView
Champions Oncology, Inc. Revenue Breakdown – FWB:2I3 - TradingView
CSBR Q4'25 Earnings: EPS estimate is (0.05) USD - TradingView
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside? - TradingView
2 Microcaps With Gross Margin Catalysts - Yahoo Finance
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation - Yahoo! Finance Canada
Champions Oncology (CSBR.US) will release its earnings report after market close on July 27. - Moomoo
Champions Oncology to announce Q4 and FY26 results on July 27 - scanx.trade
Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026 - ACCESS Newswire
Champions Oncology Schedules Year-End Results Call for 4:30 p.m. - Stock Titan
Enterprise value to EBITDA forward of Champions Oncology, Inc. – SWB:2I3 - TradingView
Brain Tumor Treatment Market Size To Exceed $7.17 Billion By 2035 - SNS Insider
RadioMedix Appoints Brian A. Markison to Board of Directors - Yahoo Finance UK
Champions Oncology (CSBR) Declines Sharply, Approaches Key Support at $5.38Volatility Stop - dars.gov.et
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – DUS:2I3 - TradingView
Enterprise value to EBIT forward of Champions Oncology, Inc. – DUS:2I3 - TradingView
Trading the Move, Not the Narrative: (CSBR) Edition - Stock Traders Daily
RXT Q1 2026 Earnings: EPS Misses Consensus by 69.49%, Shares SurgeProfit Recovery Report - dars.gov.et
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
CSBR Q4'25 Earnings: revenue estimate is 12.89M USD - TradingView
Champions Oncology (CSBR) Holds Steady Near Support as Traders Await DirectionIchimoku TK Cross - dars.gov.et
IMMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
(CSBR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Enterprise value to revenue forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight - The AI Journal
LOMA Q1 2026 Earnings: EPS Reported at 350.5 Amidst Limited DisclosuresProfit Margin Analysis - Bölüm Sonu Canavarı
ENGN Q1 2026 Earnings: Loss Narrows as EPS Beats ExpectationsFree Cash Flow Trends - dars.gov.et
Price to sales forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
AI amplifies data quality in oncology research - BioXconomy
Price to sales forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
“Publish or Perish”: Should Science Rethink Success Metrics? - Technology Networks
Price to earnings forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
0.03%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):